Developing a flexible platform for creating vaccines
A Tunable Nanophage Platform for Vaccine Development
['FUNDING_OTHER'] · UNIVERSITY OF COLORADO DENVER · NIH-11136699
This study is working on a new kind of vaccine that uses tiny particles to quickly create and test vaccines for diseases like COVID-19, aiming to give people faster access to safe and long-lasting protection against viruses.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF COLORADO DENVER (nih funded) |
| Locations | 1 site (Aurora, UNITED STATES) |
| Trial ID | NIH-11136699 on ClinicalTrials.gov |
What this research studies
This research focuses on creating a new type of vaccine platform using engineered nanoparticles called nanophages. These nanophages can be quickly modified to display various antigens, allowing for rapid testing of potential vaccines against emerging infectious diseases like COVID-19 and other coronaviruses. The approach includes advanced techniques to ensure that the vaccine candidates are stable and effective, potentially leading to single-shot vaccines that provide long-lasting immunity. Patients may benefit from faster access to effective vaccines against current and future viral threats.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for COVID-19 and other emerging viral infections, including those with compromised immune systems.
Not a fit: Patients who are not at risk for viral infections or those who have already been vaccinated may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to the rapid development of effective vaccines for COVID-19 and similar viral infections.
How similar studies have performed: Previous research has shown promise in using nanoparticle platforms for vaccine development, indicating a potential for success with this novel approach.
Where this research is happening
Aurora, UNITED STATES
- UNIVERSITY OF COLORADO DENVER — Aurora, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CATALANO, CARLOS ENRIQUE — UNIVERSITY OF COLORADO DENVER
- Study coordinator: CATALANO, CARLOS ENRIQUE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.